Hirudin as alternative anticoagulant--a historical review
Review article published in Seminars in thrombosis and hemostasis (2002)
Abstract
Advances in separation techniques and biotechnology have contributed to the development of anticoagulant agents from hematophagous animals. The most potent known natural thrombin inhibitor from blood-sucking leeches ( Hirudo medicinalis), hirudin has served as a standard for designing the natural coagulation inhibitors as an anticoagulant drug. The search for the development of hirudin from leech extract to genetically engineered products as an alternative anticoagulant has been resumed. The pharmacological profiling of the isolated thrombin inhibitor has shown that native hirudin is an antithrombotic agent of high quality. However, its clinical use has remained limited, because the substance has not been available in adequate amounts. The progress in molecular biology has stimulated the interest in the structure and function of hirudin. This development resulted in the production of recombinant hirudins (r-hirudins) through gene technology. The biological properties of hirudin combined with the ready availability of recombinant forms make the specific thrombin inhibitor well-suited for use as an antithrombotic drug. Its use should lead to a decisive progress in the management of thromboembolic diseases of both arterial and venous origin. Clinical trials, especially in diseases in which thrombin plays a crucial role, are in progress.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Advances in separation techniques and biotechnology have contributed to the development of anticoagulant agents from hematophagous animals. The most potent known natural thrombin inhibitor from blood-sucking leeches ( Hirudo medicinalis), hirudin has served as a standard for designing the natural coagulation inhibitors as an anticoagulant drug.
Why This Matters for Hirudotherapy
This review examines the historical development of hirudin — described as the most potent known natural thrombin inhibitor from Hirudo medicinalis leeches — as an alternative anticoagulant, tracing its progression from leech extracts to recombinant gene-technology products. It is directly relevant to hirudotherapy and ASH's domain because hirudin is a defining bioactive molecule derived from medicinal leeches, and the abstract discusses its pharmacological profiling as a high-quality antithrombotic agent suited for managing arterial and venous thromboembolic diseases. As a review article, it provides no original experimental or clinical outcome data, and its scope is limited to summarizing the molecular biology and pharmacological development of hirudin. Additionally, the abstract notes that clinical trials were ongoing at the time of writing, so efficacy claims reflect the authors' expectations rather than finalized results.
Citation
Hirudin as alternative anticoagulant--a historical review.
Markwardt F · Seminars in thrombosis and hemostasis, 2002
Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026